190 related articles for article (PubMed ID: 31621630)
1. Mepolizumab for the Treatment of Eosinophilic Granulomatosis With Polyangiitis: Our Experience.
Díaz Campos RM; Prudencio Ribera VC; García Moguel I; Fernández-Rodríguez C; Corral Blanco M; Jarrin Estupiñan ME; Melero Moreno C
J Investig Allergol Clin Immunol; 2019 Oct; 29(5):384-385. PubMed ID: 31621630
[No Abstract] [Full Text] [Related]
2. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
Tsurikisawa N; Oshikata C; Watanabe M; Fukuda N; Yamaguchi T; Kiyohara H; Kaneko T
Int Arch Allergy Immunol; 2021; 182(8):744-756. PubMed ID: 33887721
[TBL] [Abstract][Full Text] [Related]
3. Endobronchial Lesion in Eosinophilic Granulomatosis with Polyangiitis.
Chen GL; Wu CH; Perng WC
Iran J Allergy Asthma Immunol; 2017 Dec; 16(6):561-564. PubMed ID: 29338162
[TBL] [Abstract][Full Text] [Related]
4. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
[TBL] [Abstract][Full Text] [Related]
5. The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients.
Kitamura N; Hamaguchi M; Nishihara M; Ikumi N; Sugiyama K; Nagasawa Y; Tsuzuki H; Yoshizawa S; Tanikawa Y; Oshima M; Asatani S; Kobayashi H; Takei M
Allergol Int; 2021 Jan; 70(1):148-149. PubMed ID: 32967778
[No Abstract] [Full Text] [Related]
6. Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
Son H; Lee WJ; Moon J; Yoon S; Jung KH; Park KI; Lee SK; Chu K
J Neuroimmunol; 2021 Jun; 355():577551. PubMed ID: 33773378
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
Raffray L; Guillevin L
Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
Ennis D; Lee JK; Pagnoux C
Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
[TBL] [Abstract][Full Text] [Related]
9. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
[TBL] [Abstract][Full Text] [Related]
10. Update on eosinophilic granulomatosis with polyangiitis.
Furuta S; Iwamoto T; Nakajima H
Allergol Int; 2019 Oct; 68(4):430-436. PubMed ID: 31266709
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of mepolizumab.
Pauk N
Vnitr Lek; 2023; 69(5):322-328. PubMed ID: 37827831
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
Pradhan RR; Nepal G; Mandal S
Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
15. Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
Colantuono S; Pellicano C; Leodori G; Cilia F; Francone M; Visentini M
Allergol Int; 2020 Jul; 69(3):483-484. PubMed ID: 32224025
[No Abstract] [Full Text] [Related]
16. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
[TBL] [Abstract][Full Text] [Related]
17. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
[No Abstract] [Full Text] [Related]
18. Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis.
Miyata Y; Inoue H; Homma T; Tanaka A; Sagara H
J Investig Allergol Clin Immunol; 2021 Jul; 31(4):346-348. PubMed ID: 33030432
[No Abstract] [Full Text] [Related]
19. Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma.
Caminati M; Maule M; Nalin F; Senna G; Lunardi C
Rheumatology (Oxford); 2021 Feb; 60(2):e59-e60. PubMed ID: 32940680
[No Abstract] [Full Text] [Related]
20. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]